Videos

Colleen Kelley, MD, the biggest barriers to HIV prevention methods and how to overcome them.

Barbara Wells Trautner, MD, PhD, explains the difference between asymptomatic bacteriuria and urinary tract infections.

Ellie J. C. Goldstein, MD, discusses the global threat of resistant gram-negative rods and recently approved drugs ceftolozane tazobactam and ceftazidime avibactam.

Yoav Golan, MD, discusses trends in the incidence of acute bacterial skin and skin structure infections, standard protocols for treatment, and the challenges clinicians continue to face.

Julie Ann Justo, PharmD, MS, BCPS-AQ ID, provides an example of how institution-specific information can be used to generate a customized risk score.

Barbara Wells Trautner, MD, PhD, discusses finding alternatives to fluoroquinolones and facilitating patient communication to improve outcomes.

Ellie J C Goldstein, MD, discusses how physicians need to rely on the data that is available when selecting an antibiotic.

Dale N Gerding, MD, discusses the most recent changes to the guidelines of C difficile and the concerns of long-term effects of fecal microbiome transplants.

Julie Ann Justo, PharmD, MS, BCPS-AQ ID, discusses the source of prediction scores and how antimicrobial stewards work in concert with other clinicians to develop prediction scores.

Samuel Shor, MD, FACP, explores the controversial concept of chronic Lyme disease and the role of antibiotic stewardship in treatment programs.

Samuel, Shor, MD, FACP, discusses the potential link between chronic fatigue syndrome and Lyme disease.

Julie Ann Justo, PharmD, MS, BCPS-AQ ID, discusses how prediction scores are used to guide empiric therapy.

Barbara Wells Trautner, MD, PhD, discusses why physicians are using fluoroquinolones despite the FDA’s warning.

Douglas Krakower, MD, discusses the challenges of predicting HIV acquisition in large populations using electronic health records.

Julie Ann Justo, PharmD, MS, BCPS-AQ ID, discusses how prediction scores are used in antibiotic stewardship programs.

Barbara Wells Trautner, MD, PhD, explains the risk of aortic dissection and aneurysm in patients taking oral fluoroquinolones.

Ellie J C Goldstein, MD, stresses the importance of improving transition of care with better communication.

Jason Gallagher, PharmD, discusses the clinical implications of the approval of plazomicin for health care providers and patients.

Xingmin Sun, PhD, shares current progress on developing a vaccine for Clostridium difficile infection.

Xingmin Sun, PhD, discusses aspects that need to be considered before developing a vaccine for Clostridium difficile.

Chelsea Drennan, PharmD(c) explains why hospital length-of-stay might be shorter in patients who are on a fluoroquinolone versus a beta-lactam.

Douglas Krakower, MD, discusses which variables in electronic health records could be used to identify candidates for pre-exposure prophylaxis.

Leah H. Rubin, PhD, MPH, MA, discusses the importance of finding ways to improve cognitive function in women who are living with HIV.

Douglas Krakower, MD, explains how electronic health records have expanded in use in order to identify people at risk for diseases who could benefit from preventive interventions.

Bruce A. Mueller, PharmD, explains the risk factors for augmented renal clearance.

Kenneth P. Klinker, PharmD, and Jason M. Pogue, PharmD, share some strategies to address beta-lactam dosing issues that they employ at their institutions.

Edward J. Septimus, MD, explains how smaller hospitals can overcome the challenges that come with having fewer resources to implement a robust antibiotic stewardship program.

Jason M. Pogue, PharmD, discusses the challenges clinicians face when dosing beta-lactams based on the current guidelines.

Nathan A. Everson, PharmD, AAHIVE, shares some hidden challenges clinicians should address when implementing antibiotic stewardship interventions in the outpatient setting.

Bruce A. Mueller, PharmD, shares how clinicians in the inpatient setting can quantify acute kidney injury in adults on antibiotics.